GSK awarded contract by BARDA to support research on potential novel antibiotic
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens.
Issued: London UK
GSK and the Biomedical Advanced Research and Development Authority (BARDA) have agreed to a contract that will support the development by GSK of a potentially new antibiotic against both hospital Gram negative and biothreat pathogens.
The award will contribute to existing GSK studies and new research into biothreat pathogens such as Yersinia pestis, which causes bubonic plague and Bacillus anthracis which causes anthrax , as part of BARDA’s remit to support the advanced development of countermeasures that address emerging disease threats and public health.
GSK will initially receive $38.5 million award from BARDA over two years to contribute to the development of GSK2251052, an experimental antibiotic against a novel target, the bacterial enzyme leucyl tRNA synthetase. Additional financing may be available if BARDA exercises options for future funding, potentially bringing the total value of the award to $94.5 million.
“We welcome this agreement with BARDA, which will support the development of GSK2251052 and important research into medical countermeasures for bioterrorism,” said David Payne, head of antibacterial drug discovery at GSK. “Such innovative public-private collaborations provide an additional stimulus for anti-bacterial research and development.”
Few new antibiotic classes have entered the market in the past 40 years and the growing resistance of bacteria to treatments is creating new challenges in the management of infection.
BARDA is a division within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
About GSK2251052
GSK2251052 is a boron based antibacterial from Anacor’s boron chemistry platform and was the first compound that GSK opted to license in 2010 as part of the R&D collaboration between Anacor and GSK that was set up in 2007.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
GlaxoSmithKline Enquiries:
UK Media enquiries: David Mawdsley (020) 8047 5502
Stephen Rea (020) 8047 5502
Sarah Spencer (020) 8047 5502
Janet Morgan (020) 8047 5502
David Daley (020) 8047 5502
US Media enquiries: Nancy Pekarek (919) 483 2839
Mary Anne Rhyne (919) 483 2839
Kevin Colgan (919) 483 2839
Sarah Alspach (919) 483 2839
Jen Armstrong (919) 483 2839
Melinda Stubbee (919) 483 2839
European Analyst/Investor enquiries: Sally Ferguson (020) 8047 5543
Gary Davies (020) 8047 5503
Ziba Shamsi (020) 8047 3289
US Analyst/Investor enquiries: Tom Curry (215) 751 5419
Jeff McLaughlin (215) 751 7002
GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.
